Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Apt
read more » Discuss Add this link to...Bury Add to:
| Bookmarks